Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > International Molecular Screening Program for… >

International Molecular Screening Program for Metastatic Breast Cancer AURORA at IMPAKT

Published: May 7, 2014.
Released by Breast International Group (BIG)-aisbl  

While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored. Moreover, despite the fact that the overall breast cancer death rate has dropped steadily over the last decade and significant improvements in survival have been made, metastatic breast cancer represents the leading cause of death among patients with the disease.

In this context the Breast International Group (BIG) recently launched AURORA, which will use molecular screening to improve our understanding of metastatic breast cancer and its response or lack of response to available drug therapies. In total 1300 women and men from about 60 hospitals in 15 European countries are expected to take part in the programme. Over time, BIG hopes to expand the programme well beyond Europe to involve several 1000 more patients.

Dr Martine Piccart-Gebhart, Chair of BIG and Director of the Medicine Department of the Institut Jules Bordet, strongly believes in this research programme and says: "It is almost unethical that we continue to treat women with metastatic breast cancer when we have so little knowledge of their disease. We now have powerful technologies for investigating the molecular landscape of tumours, and we have an obligation to women to establish AURORA as a large translational research effort that can hopefully lead to more effective treatments in the future".

Within AURORA, metastatic and primary breast cancer tissue specimens will be collected and screened with a panel of more than 400 cancer-related genes for the first time on a large scale. Plasma and blood samples will also be collected, and any samples not analysed immediately will be stored in an independent bio-repository to enable future research. An innovative bioinformatics platform has been developed to support the collection of AURORA data. These data are being collected in a way that will allow sharing and collaborating in the context of other initiatives started by researchers in North America.

AURORA will enable scientists to understand both why breast cancer metastasises and why some patients respond poorly to standard treatment, while others respond very well. Whenever possible, patients participating in AURORA will be offered to participate in a clinical trial testing new and promising drugs that target the specific genetic characteristics of their tumours. The ultimate hope is that AURORA will benefit patients by leading us to both better treatments and to finding cures for the women and men affected by this disease.

The above story is based on materials provided by Breast International Group (BIG)-aisbl.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish

comments powered by Disqus

Related »

Experts Issue Plea for Better Research And Education for Advanced Breast Cancer
Breast cancer experts around the world have issued a plea to researchers, academics, drug companies, funders and advocates to …
Novel Gene Predicts Both Breast Cancer Relapse And Response to Chemotherapy
Singapore—Scientists have made it easier to predict both breast cancer relapses and responses to chemotherapy, through the identification of …
Study Opens New Prospects for Developing New Targeted Therapies for Breast Cancer
Lugano-CH, Brussels-BE, 2 May 2013 -- A study led by prominent breast cancer experts from Europe and the US …
UK Researchers Present Findings from Kentucky Breast Cancer Patients with Disease Relapse
The University of Kentucky Markey Cancer Center breast oncologist Dr. Suleiman Massarweh and his research team presented findings from …
Alternative Target for Breast Cancer Drugs
HEIDELBERG, 19 July 2013 – Scientists have identified higher levels of a receptor protein found on the surface of …

UAlberta Researchers Stop 'Vicious Cycle of Inflammation' That Leads to Tumor Growth
Drug to Reverse Breast Cancer Spread in Development
Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells. …
Blood Test Spots Recurrent Breast Cancers And Monitors Response to Treatment
Johns Hopkins Kimmel Cancer Center investigators report they have designed a blood test that accurately detects the presence of …
Everolimus Plus Exemestane Improves Bone Health in Post-menopausal Women with Advanced Breast Cancer
Vienna, Austria: Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women …
An Important Discovery in Breast Cancer by IRCM Researchers
Montréal, April 15, 2013 – A team of researchers at the IRCM, led by Dr. Jean-François Côté, made an …
Scott & White Healthcare Researchers Studying Investigational Agent That Targets Breast Cancer
Scott & White Healthcare researchers are studying an investigational agent that targets metastatic breast cancer to find if it …
What Should Be the Goal of Treatment in Metastatic Breast Cancer?
Barcelona, Spain: Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should …
Genes Associated with Aggressive Breast Cancer
Researchers at the University of Gothenburg, Sweden, have for the first time identified 12 genes that could be associated …
Gene Acts as a Brake on Breast Cancer Progression
New research out of McGill University's Goodman Cancer Research Centre provides compelling new evidence that a gene known as …
More » 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile